Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • MRP
    (1)
  • c-Fms
    (1)
  • Others
    (9)
Filter
Search Result
Results for "

zonisamide-13c-2,15n

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    14
    TargetMol | Activity
  • Natural Products
    2
    TargetMol | inventory
  • Isotope Products
    1
    TargetMol | natural
3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide
T9944246238-55-1In house
3-(9-Chloro-3-methyl-4-oxoisoxazolo[4,3-c]quinolin-5(4H)-yl)-N-(3,4,5-trimethoxyphenyl)benzeneacetamide inhibits multidrug resistance protein (MRP1).
  • $117
In Stock
Size
QTY
TargetMol | Inhibitor Sale
c-Fms-IN-13
T61589885704-58-5In house
c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50 = 17 nM) and serves as an anti-inflammatory agent.
  • $39
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Zonisamide-13C2,15N
T378471188265-58-8
Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with Ki values of 218, 56, 35, and 21 nM, respectively.4,5 In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED50s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid or dihydroxyphenyl acetic acid , and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy. |1. Masuda, Y., Ishizaki, M., and Shimizu, M. Zonisamide: Pharmacology and clinical efficacy in epilepsy. CNS Drug Rev. 4(4), 341-360 (1998).|2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 3(2), 138-143 (1989).|3. Suzuki, S., Kawakami, K., Nishimura, S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res. 12(1), 21-27 (1992).|4. Nishimori, I., Vullo, D., Minakuchi, T., et al. Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori. Bioorg. Med. Chem. Lett. 16(8), 2182-2188 (2006).|5. De Simone, G., Di Fiore, A., Menchise, V., et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies. Bioorg. Med. Chem. Lett. 15(9), 2315-2320 (2005).|6. Yabe, H., Choudhury, M.E., Kubo, M., et al. Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP. J. Pharmacol. Sci. 110(1), 64-68 (2009).
  • $990
35 days
Size
QTY
c-Met-IN-13
T638852377724-93-9
c-Met-IN-13 is a potent inhibitor of c-Met (IC50: 2.43 nM) that exhibits significant cytotoxicity and anti-proliferative effects against cancer cells in a concentration-dependent and time-dependent manner, demonstrating therapeutic potential against cancer.
  • $1,520
6-8 weeks
Size
QTY
2-Chloro-2’-C-methyl-6-N,N-dimethyladenosine
TNU01112095417-43-7
2’-C-Methyl nucleoside; Halo-nucleoside; 2/6/8-Modified purine nucleoside
  • Inquiry Price
7-10 days
Size
QTY
N-Methyltaxol C
TN4616153083-53-5
N-methyltaxol C and paclitaxel can produce a positive inotropic effect in papillary muscle, without alterations in the action potential. They can induced conduction arrhythmias and reduce coronary flow and left ventricular systolic pressure in the isolate
  • $920
Backorder
Size
QTY
N'-Phenacylpiperazineinnuchenenolide C
T131470
N'-Phenacylpiperazineinnuchenenolide C is a useful organic compound for research related to life sciences and the catalog number is T131470.
  • Inquiry Price
Size
QTY
N-Trityl-N4-benzoyl-morpholino-C-5’-O-phosphoramidite
TNU1469
N-Trityl-N4-benzoyl-morpholino-C-5'-O-phosphoramidite is a Nucleoside Derivative - Morpholino nucleoside; Phosphoramidite.
  • Inquiry Price
7-10 days
Size
QTY
5'-ODMT cEt N-Bzm5 C Phosphoramidite (Amidite)
T747041197033-17-2
5'-ODMT cEt N-Bzm5 C Phosphoramidite Amidite is a potent nucleic acid analog and a modified antisense oligonucleotide [1].
  • $279
8-10 weeks
Size
QTY
Bis[2-(1-isoquinolinyl-N)phenyl-C](2,4-pentanedionato-O2,O4)iridium(III)
T67275435294-03-4
Bis[2-(1-isoquinolinyl-N)phenyl-C](2,4-pentanedionato-O2,O4)iridium(III) is a useful organic compound for research related to life sciences. The catalog number is T67275 and the CAS number is 435294-03-4.
    7-10 days
    Inquiry
    7-N-(4-Hydroxyphenyl)mitomycin C
    T2948770343-57-6
    7-N-(4-Hydroxyphenyl)mitomycin C is a bioactive chemical.
    • Inquiry Price
    Size
    QTY
    (1'R,3a'R,8a'S,9'S,9a'S)-1'-Methyl-3'-oxo-N,N-diphenyl-3',3a',5',7',8',8a',9',9a'-octahydro-1'H-spiro[[1,3]dioxolane-2,6'-naphtho[2,3-c]furan]-9'-carboxamide
    T67324900160-98-7
    (1'R,3a'R,8a'S,9'S,9a'S)-1'-Methyl-3'-oxo-N,N-diphenyl-3',3a',5',7',8',8a',9',9a'-octahydro-1'H-spiro[[1,3]dioxolane-2,6'-naphtho[2,3-c]furan]-9'-carboxamide is a useful organic compound for research related to life sciences. The catalog number is T67324 and the CAS number is 900160-98-7.
      7-10 days
      Inquiry
      Zonisamide
      T026768291-97-4
      Zonisamide (AD 810), a sulfonamide anticonvulsant, is approved for use as an adjunctive treatment in adults with partial-onset seizures. It may inhibit a carbonic anhydrase although this is not one of the main mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels results in a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may lower the uptake of the inhibitory neurotransmitter GABA while increasing the uptake of the excitatory neurotransmitter glutamate.
      • $40
      In Stock
      Size
      QTY
      TargetMol | Inhibitor Sale
      TargetMol | Citations Cited
      Zonisamide sodium
      T2356768291-98-5
      Zonisamide sodium is a 1,2 benzisoxazole derivative. It is the first agent of this chemical class to be developed as an antiepileptic drug.
      • $1,520
      1-2 weeks
      Size
      QTY